NxStage Medical, Inc. (NASDAQ:NXTM) President Joseph E. Turk, Jr. sold 1,000 shares of NxStage Medical stock in a transaction dated Wednesday, October 4th. The stock was sold at an average price of $27.56, for a total value of $27,560.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Shares of NxStage Medical, Inc. (NASDAQ:NXTM) traded down 0.07% during trading on Friday, hitting $27.61. The stock had a trading volume of 7,499 shares. The stock’s 50-day moving average is $27.91 and its 200-day moving average is $25.85. The stock’s market cap is $1.82 billion. NxStage Medical, Inc. has a 12-month low of $20.45 and a 12-month high of $30.80.

NxStage Medical (NASDAQ:NXTM) last announced its earnings results on Monday, August 7th. The medical device company reported ($0.03) earnings per share for the quarter, hitting the consensus estimate of ($0.03). NxStage Medical had a negative net margin of 1.33% and a negative return on equity of 2.43%. The business had revenue of $92.20 million during the quarter, compared to the consensus estimate of $96.47 million. During the same quarter in the prior year, the firm earned ($0.03) earnings per share. The business’s quarterly revenue was up .0% compared to the same quarter last year. On average, equities research analysts expect that NxStage Medical, Inc. will post ($0.05) EPS for the current year.

TRADEMARK VIOLATION WARNING: This report was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://www.watchlistnews.com/joseph-e-turk-jr-sells-1000-shares-of-nxstage-medical-inc-nxtm-stock/1612603.html.

Institutional investors and hedge funds have recently made changes to their positions in the company. CWM LLC acquired a new stake in shares of NxStage Medical during the second quarter worth about $2,684,000. Birchview Capital LP boosted its stake in shares of NxStage Medical by 21.3% during the second quarter. Birchview Capital LP now owns 34,200 shares of the medical device company’s stock worth $857,000 after buying an additional 6,000 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of NxStage Medical by 0.5% during the first quarter. Bank of New York Mellon Corp now owns 639,866 shares of the medical device company’s stock worth $17,168,000 after buying an additional 2,914 shares during the period. Russell Investments Group Ltd. boosted its stake in shares of NxStage Medical by 67.9% during the first quarter. Russell Investments Group Ltd. now owns 28,847 shares of the medical device company’s stock worth $773,000 after buying an additional 11,668 shares during the period. Finally, Schwab Charles Investment Management Inc. boosted its stake in shares of NxStage Medical by 7.0% during the first quarter. Schwab Charles Investment Management Inc. now owns 277,899 shares of the medical device company’s stock worth $7,457,000 after buying an additional 18,189 shares during the period. Institutional investors and hedge funds own 92.66% of the company’s stock.

A number of brokerages have commented on NXTM. William Blair cut NxStage Medical from an “outperform” rating to a “market perform” rating in a research report on Monday, August 7th. Zacks Investment Research raised NxStage Medical from a “hold” rating to a “buy” rating and set a $33.00 price target for the company in a research report on Thursday, August 10th. Leerink Swann cut NxStage Medical from an “outperform” rating to a “market perform” rating and lifted their price target for the stock from $28.00 to $30.00 in a research report on Tuesday, August 22nd. Craig Hallum began coverage on NxStage Medical in a research report on Tuesday, June 27th. They set a “buy” rating and a $32.00 price target for the company. Finally, Canaccord Genuity cut NxStage Medical from a “buy” rating to a “hold” rating and set a $30.00 price target for the company. in a research report on Monday, August 7th. One investment analyst has rated the stock with a sell rating and nine have assigned a hold rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $30.25.

NxStage Medical Company Profile

NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.

Insider Buying and Selling by Quarter for NxStage Medical (NASDAQ:NXTM)

Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.